Claudio Gobbi

Claudio Gobbi
is currently collaborating with
Neurocentro - Istituto di Neuroscienze cliniche della Svizzera italiana (INSI) (Rif. INSI)
Via Tesserete 46
6900 Lugano

Claudio Gobbi
on behalf of
Neurocentro - Istituto di Neuroscienze cliniche della Svizzera italiana (INSI) EOC (Rif. INSI)
is currently participating in the Research Group
Neuromuscular disorders
as Group Leader [Rif. 55110]

Claudio Gobbi
on behalf of
Neurocentro - Istituto di Neuroscienze cliniche della Svizzera italiana (INSI) EOC (Rif. INSI)
is currently participating in the Research Group
Multiple sclerosis
as Group Leader [Rif. 55110]

Claudio Gobbi has participated - as a whole - in 85 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones participated along with Giulio Disanto

1) De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study

2) Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS

3) Efficacy and safety of the implantable, magnetic resonance imaging-compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients

4) Contribution of sleep disturbances to fatigue in multiple sclerosis: a prospective study using clinical and polysomnographic parameters

5) Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years

6) Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping

7) Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

8) A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients

9) Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year

10) Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies

11) Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

12) Leg movement activity during sleep in multiple sclerosis with and without restless legs syndrome

13) Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

14) Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis

15) Restless Legs Syndrome and Periodic Limb Movements in 86 patients with Multiple Sclerosis

16) A randomized pilot trial of oral prednisone taper vs placebo following iv methylprednisolone for multiple sclerosis relapses: Effects on adrenal function and clinical efficacy

17) Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis

18) Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients

19) Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study

20) De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis

Claudio Gobbi has participated - as a whole - in 85 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones participated along with Giulio Disanto